Evaluating the impact of HIV pre-exposure prophylaxis on pregnancy, infant, and maternal health outcomes in Malawi: PrIMO study protocol

• Príomhchruthaitheoirí: Friday Saidi (Údar), Sanya Shah (Údar), Madeleine Squibb (Údar), Lameck Chinula (Údar), Charity Nakanga (Údar), Tisungane Mvalo (Údar), Mitch Matoga (Údar), Agatha K. Bula (Údar), Maganizo B. Chagomerana (Údar), Funny Kamanga (Údar), Wiza Kumwenda (Údar), Tawonga Mkochi (Údar), Gladwell Masiye (Údar), Ida Moya (Údar), Michael E. Herce (Údar), Sarah E. Rutstein (Údar), Virginia Thonyiwa (Údar), Rose K. Nyirenda (Údar), Victor Mwapasa (Údar), Irving Hoffman (Údar), Mina C. Hosseinipour (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: BMC, 2024-09-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Abstract Background Incident HIV during the perinatal period significantly impedes elimination of Mother-to-Child HIV Transmission (eMTCT) efforts. Pre-Exposure Prophylaxis (PrEP) effectively reduces HIV acquisition, and new agents like injectable Cabotegravir (CAB-LA) offer potential advantages for...